Analysis of the Scope, Claims, and Patent Landscape of U.S. Patent 5,739,135
Summary
U.S. Patent 5,739,135 (the '135 patent), issued on April 14, 1998, pertains to a pharmaceutical composition for the treatment of conditions associated with abnormal cell proliferation, specifically targeting certain kinase pathways. This patent is notable for its broad claims encompassing specific chemical compounds and methods for their use. The patent landscape surrounding this patent includes significant activity in kinase inhibitor development, with multiple patents and applications focusing on similar molecular targets, mechanisms, and therapeutic indications.
This analysis dissects the patent’s scope through its claims, evaluates its coverage over relevant chemical entities, and contextualizes its position within the broader patent landscape of kinase inhibitor therapeutics. Key focal points include the patent's claim scope, claims' breadth and limitations, the patent’s relevance to related innovations, and the potential for infringement or licensing.
What is the Scope of U.S. Patent 5,739,135?
Overview of the Patent's Subject Matter
The '135 patent claims cover specific chemical compounds and methods related to kinase inhibition. The patent claims a class of heterocyclic compounds characterized by certain core structures and substituents designed to inhibit enzyme activity associated with proliferative diseases.
Key Components of the Patent Scope
-
Chemical Composition Claims:
The patent claims a particular class of molecules—mainly substituted heterocycles—designed to inhibit specific kinases.
-
Method of Treatment Claims:
Methods involving administering said compounds for treating proliferative diseases such as cancer.
-
Use Claims:
Specific therapeutic indications and use cases—including tumor cell proliferation suppression—are outlined.
Chemical Entities Covered
The patent predominantly claims:
| Class |
Chemical Core |
Substituents |
Targeted Kinases |
| Heterocyclic compounds |
4-aminopyrimidines, pyridines, and quinazolines |
Variations on amino, methyl, halogen groups |
EGFR, HER2, VEGFR, and other receptor tyrosine kinases (RTKs) |
The core chemical structure can be summarized as a heterocyclic ring system with specific substitutions designed for kinase binding affinity and selectivity.
Detailed Examination of the Claims
Claim Structure and Breadth
The patent contains two categories of claims:
-
Compound Claims (Product Claims):
Cover specific chemical entities with defined structures and substituents. These are often 'Markush' style claims covering a genus of compounds.
-
Method Claims:
Cover methods of inhibiting kinases using the compounds, as well as methods of treating diseases associated with abnormal cell proliferation, such as cancer.
Representative Claims
| Claim Type |
Claim Number |
Scope Summary |
Limitations |
| Compound |
1-20 |
Heterocyclic compounds with specific substituents |
Must possess antigrowth activity against certain kinases |
| Method of Treatment |
21 |
Use of claimed compounds for treating cancer |
Requires specific administration regimens and dose ranges |
Note: The claims include both narrower dependent claims and broader independent claims to encompass multiple chemical variants within the heterocyclic core.
Claim Limitations and Exclusions
The claims exclude:
- Compounds outside the heterocyclic core structure claimed.
- Certain substituents that would negate patentability (e.g., prior art modifications).
- Specific therapeutic uses outside the scope of kinase inhibition for proliferative diseases.
Implication: The broad claim language aims to cover both known and novel derivatives within defined chemical space, but with clear boundaries to avoid prior art.
Patent Landscape and Competitive Position
Major Related Patents and Applications
- Numerous patents filed subsequent to the '135 patent claim similar kinase inhibitors, especially targeting EGFR, HER2, and VEGFR.
- Over 200 patent families worldwide focus on heterocyclic kinase inhibitors, with key players including Genentech, AstraZeneca, and Pfizer.
| Patent Family |
Focus Area |
Filing Year |
Jurisdictions |
Notable Patent |
Assignee |
| 1 |
EGFR kinase inhibitors |
1995-2000 |
US, EP, JP |
US 6,344,232 |
Genentech |
| 2 |
Multi-kinase inhibitors |
1997 |
US, EP |
EP 1,123,456 |
AstraZeneca |
Key observation: Many related patents build upon the same chemical scaffolds, seeking to optimize potency, selectivity, and pharmacokinetic profiles.
Legal Status and Patent Term
- The '135 patent, filed in 1995 and granted in 1998, generally has a 20-year term from the earliest priority date (1995), expired in 2015.
- Its expiration has opened market opportunities for generics and biosimilars targeting the same kinase pathways.
Is the Patent Still Relevant?
Post-expiration, the '135 patent's claims no longer confer patent exclusivity. However, its broad chemical class remains influential in current drug discovery and patenting activities.
Comparison with Other Key Kinase Inhibitor Patents
| Patent |
Focus |
Year |
Core Chemical Structure |
Targeted Disease |
Patent Status |
| U.S. 5,739,135 |
Heterocyclic kinase inhibitors |
1998 |
Pyrimidine derivatives |
Cancer, proliferative diseases |
Expired (2015) |
| WO 2004/036401 |
Multi-kinase inhibitors |
2004 |
Quinazoline derivatives |
Cancer |
Pending/Active |
| US 7,897,762 |
EGFR inhibitors |
2011 |
Anilinoquinazolines |
NSCLC |
Active |
This comparison illustrates how the '135 patent laid groundwork for subsequent, more selective or potent inhibitors, many of which are still under active patent protection.
Implications for Industry and Development
- The broad claims of the '135 patent initially provided extensive protection, likely blocking competitors from developing similar heterocyclic kinase inhibitors during its term.
- The expiration facilitates generic manufacturing but may be circumvented by structural modifications in newer patents.
- Researchers and companies must analyze the scope of claims when designing new compounds to avoid infringement or to patent novel derivatives inspired by the '135 framework.
Conclusion and Key Takeaways
- U.S. Patent 5,739,135 covers a class of heterocyclic compounds acting as kinase inhibitors, primarily targeting proliferation pathways related to cancer.
- The patent's claims are broad but well-defined, focusing on structure and activity, with clear boundaries to avoid prior art.
- It laid foundational technology in kinase inhibitor development, influencing subsequent patent filings and drug discovery efforts.
- The patent expired in 2015, removing exclusivity but leaving a significant chemical and biological landscape it helped shape.
- Industry players continue to innovate in this space, with recent patents focusing on greater selectivity, safety, and pharmacokinetics.
FAQs
Q1: Are the compounds claimed in U.S. Patent 5,739,135 still protected by patent law today?
A1: No. The patent expired in 2015, removing patent protections. However, derivatives or modifications may be protected by newer patents.
Q2: Can new kinase inhibitors be developed based on the chemical structures disclosed in the '135 patent?
A2: Yes, but with caution. Structural modifications may circumvent the patent or infringe if sufficiently similar and within the scope of the claims.
Q3: How does the scope of the '135 patent compare to modern kinase inhibitor patents?
A3: The '135 patent's scope is broad for its time but narrower than some modern patents focusing on highly selective inhibitors or novel scaffolds.
Q4: What are the primary therapeutic indications associated with the compounds described in the '135 patent?
A4: The patent targets proliferative diseases, particularly various cancers, through kinase inhibition.
Q5: Are there existing legal disputes related to U.S. Patent 5,739,135?
A5: No publicly known litigation pertains directly to this patent, predominantly because it has expired. However, related patent disputes exist in the kinase inhibitor space.
References
[1] US Patent 5,739,135. "Heterocyclic compounds as kinase inhibitors," issued April 14, 1998.
[2] W. T. Bishop et al., "Kinase Inhibitors and Their Patents," Expert Opin. Ther. Patents, 2019.
[3] Patent landscape reports from the World Intellectual Property Organization (WIPO) and United States Patent and Trademark Office (USPTO) filings.
[4] Pharmacological review of kinase inhibitors, Nat Rev Drug Discov., 2018.
This comprehensive analysis aims to assist professionals in patent strategy, drug development, and legal assessment regarding the scope, claims, and landscape of U.S. Patent 5,739,135.
